Anavex Life Sciences (NASDAQ:AVXL) Earns “Buy” Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of Anavex Life Sciences (NASDAQ:AVXL) in a report released on Friday morning, MarketBeat Ratings reports. The brokerage currently has a $40.00 price objective on the biotechnology company’s stock.

Separately, EF Hutton Acquisition Co. I raised Anavex Life Sciences to a “strong-buy” rating in a report on Monday, July 22nd.

Anavex Life Sciences Price Performance

Shares of Anavex Life Sciences stock opened at $5.65 on Friday. The stock has a market capitalization of $478.23 million, a price-to-earnings ratio of -11.30 and a beta of 0.61. The firm’s fifty day simple moving average is $5.68 and its 200-day simple moving average is $4.95. Anavex Life Sciences has a 12 month low of $3.25 and a 12 month high of $10.45.

Anavex Life Sciences (NASDAQ:AVXL) last announced its earnings results on Tuesday, August 6th. The biotechnology company reported ($0.14) EPS for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.01. During the same quarter in the previous year, the firm earned ($0.14) earnings per share. Analysts anticipate that Anavex Life Sciences will post -0.55 earnings per share for the current year.

Institutional Trading of Anavex Life Sciences

Several hedge funds and other institutional investors have recently made changes to their positions in AVXL. Jupiter Asset Management Ltd. lifted its position in Anavex Life Sciences by 675.0% in the first quarter. Jupiter Asset Management Ltd. now owns 804,642 shares of the biotechnology company’s stock valued at $4,096,000 after purchasing an additional 700,812 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Anavex Life Sciences by 30.2% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 54,850 shares of the biotechnology company’s stock valued at $279,000 after buying an additional 12,728 shares during the period. Renaissance Technologies LLC boosted its stake in shares of Anavex Life Sciences by 483.8% in the second quarter. Renaissance Technologies LLC now owns 466,437 shares of the biotechnology company’s stock valued at $1,968,000 after buying an additional 386,537 shares in the last quarter. Los Angeles Capital Management LLC grew its holdings in Anavex Life Sciences by 51.4% during the first quarter. Los Angeles Capital Management LLC now owns 87,931 shares of the biotechnology company’s stock worth $448,000 after acquiring an additional 29,844 shares during the period. Finally, Virtu Financial LLC raised its position in Anavex Life Sciences by 87.5% in the first quarter. Virtu Financial LLC now owns 40,612 shares of the biotechnology company’s stock worth $207,000 after acquiring an additional 18,954 shares in the last quarter. Hedge funds and other institutional investors own 31.55% of the company’s stock.

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.